Tradjenta is prescribed for the treatment of type 2 diabetes in adults. This medication works to control blood sugar levels by increasing the production of insulin following a meal and by decreasing the amount of glucose (sugar) produced by the liver. Tradjenta is now approved for use in combination with insulin.
Tradjenta™ (linagliptin) is a prescription medication used to treat type 2 diabetes. This medicine should be used in combination with appropriate changes in diet and exercise to help control blood sugar levels. It can be used alone or in combination with other diabetes medications, including insulin.
Type 2 diabetes is the most common type of diabetes (see Diabetes Types). It is also sometimes called adult-onset diabetes or noninsulin-dependent diabetes. Type 2 diabetes is a condition in which the cells in the body do not respond to insulin as well as they normally should. As a result, the cells do not adequately remove sugar from the blood. This is why people with type 2 diabetes have high blood sugar levels.
Over time, high blood sugar levels can lead to a number of problems, including diabetic impotence, diabetic neuropathy, kidney failure, and heart disease (see Diabetes Complications). The cause of type 2 diabetes is not fully understood, although it is known that obesity and genetics play an important role in the development of the disease.
Any type 2 diabetes treatment begins with lifestyle changes, such as weight loss, a diabetic diet, and exercise. If lifestyle changes are not effective at managing diabetes, diabetes medication, such as Tradjenta, may be necessary.
Some diabetes drugs force the pancreas to produce more insulin regardless of blood sugar levels. These medications are effective, but can cause dangerously low blood sugar levels (hypoglycemia). Because of the way Tradjenta works, it is far less likely to cause dangerously low blood sugar levels, compared with some other diabetes medications.
(To learn about controlling diabetes through lifestyle changes, click on any of the links below: